Becton, Dickinson and Company

702 articles with Becton, Dickinson and Company

• BD Hits 2 Billion Injection Device Milestone in Support of Global COVID-19 Vaccination Efforts

  6/8/2021

  BD, a leading global medical technology company, announced that it has received pandemic orders for needles and syringes totaling 2 billion injection devices to support global COVID-19 vaccination efforts.

• BD Advances Leadership in Cybersecurity Preparedness, Transparency

  6/2/2021

  BD, a leading global medical technology company, announced that it has become the first medical technology company authorized as a Common Vulnerability and Exposures Numbering Authority by the CVE Program, further demonstrating the company's leadership in health care cybersecurity.

• BD Leverages Artificial Intelligence To Transform Microbiology Urine Testing

  5/26/2021

  BD, a leading global medical technology company, announced the U.S. launch of a Urine Culture Application for use with the BD Kiestra™ lab automation incubation and imaging system that can transform the way microbiology labs approach urine culture analysis.

• BD to Present at Upcoming Investor Conferences in June 2021

  5/26/2021

  BD, a leading global medical technology company, announced that it will present at the following upcoming virtual investor conferences during the month of June

• BD Launches Industry First Ready-to-Use Iodine-Based Surgical Irrigation System

  5/25/2021

  BD Surgiphor™ sterile wound irrigation system delivers simplified sterility and helps hospitals comply with national and international guidelines[1,2]

• BD to Build New €165 Million Manufacturing Facility in Zaragoza, Spain To Support Ongoing Strong Growth of Pre-Filled Drug Delivery Business

  5/18/2021

  New plant will produce drug delivery devices, employ 150 people in 2024 and up to 600 when full operations start in 2030

• BD Announces Industry-First CE Marked Assay for HPV Screening from At-Home Self-Collected Vaginal Samples

  5/13/2021

  BD, a leading global medical technology company, announced the industry's first self-collection claim for HPV screening has been CE marked to the IVD directive 98/79/EC.

• BD Announces Second Fiscal Quarter Results; Reaffirms Fiscal 2021 Guidance

  5/6/2021

  BD, a leading global medical technology company, reported quarterly revenues of $4.9 billion for the second fiscal quarter ended March 31, 2021.

• BD Announces Intent to Spin Off Diabetes Care Business to Enhance Focus on Innovation and Priority Growth Markets

  5/6/2021

  Management will provide further details during the company's announced fiscal second quarter results call today at 8 a.m. Eastern Time.

• BD Announces Enrollment in Post-Market Studies of the WavelinQ™ Arteriovenous Endovascular Fistula

  4/29/2021

  BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that enrollment has begun and the first patients have been treated in the post-market surveillance study, CONNECT-AV.

• Elizabeth McCombs Appointed Chief Technology Officer at BD

  4/28/2021

   BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Elizabeth McCombs as executive vice president and chief technology officer, effective April 26, 2021

• CerTest Biotec, BD Announce Addition of Saliva to the CE Marked VIASURE SARS-CoV-2 (N1+N2) Real Time PCR Detection Kit for BD MAX™ Molecular Diagnostic System

  4/27/2021

  CerTest Biotec, along with BD, a leading global medical technology company, announced the VIASURE SARS-CoV-2 Real Time PCR Detection Kit for the BD MAX™ Molecular Diagnostic System can now be run on saliva specimens.

• BD Board Declares Dividend - Apr 27, 2021

  4/27/2021

  The Board of Directors of BD has declared a quarterly dividend of $0.83 per common share, payable on June 30, 2021 to holders of record on June 9, 2021.

• BD Announces FDA 510(k) Submission for BD Alaris™ System

  4/26/2021

  BD, a leading global medical technology company, announced it has submitted a 510 premarket notification to the U.S. Food and Drug Administration for the BD Alaris™ System, the most widely used infusion pump in acute care hospitals across the United States.

• BD's Commitment to Address Climate Change

  4/22/2021

  In recognition of Earth Day, BD, a leading global medical technology company, reinforces its commitment to Advancing the world of health™ by affirming the first phase of its 2030+ sustainability goals – climate change targets.

• BD Commits $1M To Fight Maternal And Neonatal Tetanus

  4/20/2021

  Company continues its commitment to expanding health care access through its long-standing support of UNICEF USA and their efforts to eliminate Maternal and Neonatal Tetanus

• BD To Announce Financial Results For Its Second Quarter Of Fiscal 2021

  4/5/2021

   BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will report its financial results for the second quarter of fiscal year 2021 on Thursday, May 6, 2021 .

• BD Receives Emergency Use Authorization for Asymptomatic Screening for SARS-CoV-2 through Serial Rapid Antigen Testing

  4/1/2021

  BD Veritor™ Plus System supports return-to-school and return-to-work programs through serial testing

• BD to Invest $65 Million for Key Supply Chain Infrastructure in Tucson, Arizona to Increase Resiliency of U.S. Medical Device Supply

  4/1/2021

  BD, a leading global medical technology company, announced it will invest $65 million to construct a state-of-the-art facility in Tucson, Arizona that will be a hub for the company's supply chain, serving as a final-stage manufacturing and sterilization center.

• BD Announces FDA Emergency Use Authorization for Combination COVID-19, Flu Rapid Antigen Test

  3/30/2021

  New Test on the BD Veritor™ Plus System Can Detect SARS-CoV-2, Influenza A, Influenza B from Single Patient Sample